Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Reset

1 trials match this view; 4 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 108 across 1 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Export filtered registry facts · JSONInteractive world mapGermany source-checked report

Recorded study-start years

202511

Current indexed registry status

Recruiting11

Reported research conditions

COPD (Chronic Obstructive Pulmonary Disease)11
ALS (Amyotrophic Lateral Sclerosis)11
MS (Multiple Sclerosis)11
Major Depressive Disorder (MDD)11
Atypical Parkinson Disease11

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Matching trial records

1 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.

NCT06782724

COPD (Chronic Obstructive Pulmonary Disease) · ALS (Amyotrophic Lateral Sclerosis) · MS (Multiple Sclerosis) · Major Depressive Disorder (MDD) · Atypical Parkinson Disease		University Medical Center Groningen

PHASE2

Recruiting

Registry updated 2026-05-08

108

ESTIMATED

2025-07-01
2027-01-01
2028-01-01

Reported research facilities

National Institute of Mental HealthPrague, Czechia
Bispebjerg HospitalCopenhagen, Denmark
University Medical Center GroningenGroningen, Provincie Groningen, Netherlands
Champalimaud FoundationLisbon, Portugal

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.